What Makes Brain Metastases in Lung Cancer So Hard to Treat? New Research Reveals Key Immune Differences

Brain Metastasis | Expert Surgeon | Aaron Cohen-Gadol, MD
For patients with non-small cell lung cancer (NSCLC), brain metastases are one of the most serious and deadly complications. Even with surgery, radiation, and chemotherapy, the prognosis remains poor—most patients survive only about 7 months after diagnosis. A major reason for this challenge may lie in how the immune environment of brain metastases differs from that of the original lung tumors.

A new study has taken a deep dive into this question by analyzing immune markers in tumor samples from both primary lung cancers and their paired brain metastases. The findings reveal that the immune landscape in the brain is significantly more suppressive and may help explain why some immunotherapies don’t work as well on brain metastases.

The Big Question: Are Primary Tumors and Brain Metastases the Same Immunologically?

Researchers collected and analyzed tissue samples from 62 NSCLC patients with brain metastases. They examined:

  • 17 matched pairs of primary lung tumors and their brain metastases

  • 45 additional brain metastasis samples

They used various markers to study immune checkpoint proteins (like PD-1, PD-L1, B7-H3, B7-H4, IDO1), immune cells (T cells, B cells, macrophages), and other tumor characteristics.

What They Found

  1. Brain Metastases Have Fewer Immune Cells

    • Compared to the original lung tumors, brain metastases had significantly fewer tumor-infiltrating lymphocytes (TILs), including CD3+, CD4+, CD8+, and CD20+ cells.

    • This suggests that the brain’s immune environment is more suppressive, making it harder for the body’s natural defenses to attack tumors.

  2. Some Immune Markers Vary Between Lung and Brain

    • The expression of proteins like PD-L1, B7-H3, B7-H4, IDO1, and EphA2 differed between the original tumor and brain metastases.

    • Notably, B7-H4 and CD68 (a macrophage marker) were associated with worse outcomes in patients.

  3. Timing of Metastasis Affects the Immune Environment

    • In cases where brain metastases appeared at the same time as the lung cancer (synchronous), the brain tumors were more likely to express PD-L1 and have fewer CD8+ T cells.

    • In contrast, in patients where brain metastases developed later (metachronous), PD-L1 expression was much lower.

  4. Prognostic Indicators

    • High expression of B7-H4 and high infiltration of CD68+ macrophages were linked to significantly worse survival.

    • Interestingly, other well-known markers like PD-1, PD-L1, and B7-H3 did not show a clear correlation with patient outcomes in brain metastases.

  5. Why This Matters Clinically

    • Because many treatment decisions are based on immune markers found in the primary lung tumor, this mismatch in immune environments could explain why some treatments fail when the cancer spreads to the brain.

    • Knowing which markers truly matter in brain metastases (like B7-H4 and CD68+ TAMs) could help doctors make better treatment decisions.

What Does This Mean for Immunotherapy?

While immunotherapy has shown success in treating NSCLC, its effect on brain metastases is limited. This study emphasizes that:

  • The brain's unique immune environment may make it more resistant to immune-based therapies.

  • New targets like B7-H4 and CD68+ macrophages might be better suited for treating brain metastases.

  • A more personalized approach, considering both primary and metastatic tumors, may be essential for effective care.

Popular Posts